Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir by de Kanter, C.T. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
H I V / A I D S M A J O R A R T I C L E
Lack of a Clinically Signiﬁcant Drug–Drug
Interaction in Healthy Volunteers Between the
Hepatitis C Virus Protease Inhibitor Boceprevir
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Background. Patients coinfected with human immunodeﬁciency virus (HIV) and hepatitis C virus (HCV) are
likely to use both HIV and HCV treatment. Drug–drug interactions have been demonstrated between boceprevir, an
HCV protease inhibitor, and frequently prescribed antiretroviral drugs, such as efavirenz and boosted HIV protease
inhibitors. Concomitant administration of boceprevir with these drugs should be avoided. This study was designed to
investigate the absence of a drug-drug interaction between boceprevir and raltegravir, an HIV integrase inhibitor.
Methods. This was an open-label, randomized, 2-period, crossover phase 1 trial in 24 healthy volunteers. All sub-
jects were randomly assigned to receive boceprevir 800 mg every 8 hours for 9 days plus a single dose of raltegravir 400
mg on day 10 followed by a washout period and a single dose of raltegravir 400 mg on day 38, or the same medication
in reverse order. Blood samples for pharmacokinetics were collected and pharmacokinetic parameters were calculated.
Results. The geometric mean (GM) of raltegravir area under the concentration-time curve (AUC)0–12h and
maximum plasma concentration (Cmax) for raltegravir + boceprevir vs raltegravir alone were 4.27 (95% conﬁdence in-
terval [CI], 3.22–5.66) vs 4.04 (95% CI, 3.09–5.28) mg  hour/L and 1.06 (95% CI, .76–1.49) vs 0.93 (95% CI, .70–1.23)
mg/L, respectively. GM ratio estimates of raltegravir AUC0–12h and Cmax for raltegravir + boceprevir vs raltegravir alone
were 1.04 (90% CI, .88–1.22) and 1.11 (90% CI, .91–1.36), respectively. The GM of boceprevir AUC0–8h, Cmax, and C8h
were 5.45 (95% CI, 5.11–5.81) mg  hour/L, 1.88 (95% CI, 1.72–2.06) mg/L, and 0.09 (95% CI, .07–.11) mg/L, respec-
tively. These data are comparable to those from historical controls.
Conclusions. Due to the absence of a clinically signiﬁcant drug interaction, raltegravir can be recommended for
combined HIV/HCV treatment including boceprevir.
Clinical Trials Registration. NCT01288417.
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The prevalence of hepatitis C virus (HCV) and human
immunodeﬁciency virus (HIV) coinfection ranges
from ±10% to 70% in Europe and North America [1].
Since the introduction of combination antiretroviral
therapy (cART), the life expectancy of HIV-infected
patients has improved dramatically. Since then, liver-
related deaths have become the most frequent cause of
non-AIDS-related deaths, to which HCV coinfection
makes a substantial contribution [2].
The NS3 serine protease inhibitors boceprevir and
telaprevir have been approved since 2011 for use in
patients with chronic HCV genotype 1 infection.
When added to the standard of care, sustained
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virological response (SVR) rates improve by 25%–31% shown
in HCV monoinfected patients [3, 4]. In total SVR rates
around 68–75% are seen.
According to US guidelines, ﬁrst-line cART for HIV-infected
patients should consist of the 2 nucleoside reverse transcriptase
inhibitors (NRTIs) tenofovir and emtricitabine, in combination
with the nonnucleoside reverse transcriptase inhibitor efavirenz,
the ritonavir-boosted HIV protease inhibitors atazanavir or dar-
unavir, or the integrase inhibitor raltegravir [5].
As HIV/HCV-coinfected patients are likely to use both HIV
and HCV treatment, including the HCV protease inhibitors,
simultaneously, it is important to know if drug–drug interac-
tions occur. At this moment it is not recommended to coad-
minister boceprevir with darunavir/ritonavir, lopinavir/
ritonavir, or efavirenz because decreased concentrations of bo-
ceprevir, as well as decreased concentrations of the boosted
HIV protease inhibitors, have been found [6, 7]. Because the
combination with atazanavir/ritonavir did not substantially in-
ﬂuence boceprevir concentrations, although atazanavir levels
were lower, coadministration of these drugs can be considered
on a case-by-case basis [7]. The only remaining ﬁrst-line anti-
retroviral agent that can be added to an NRTI backbone is
raltegravir. Raltegravir is a substrate of UDP-glucuronosyl-
transferase (UGT) and does not inﬂuence cytochrome P450
(CYP) enzymes; boceprevir is a substrate of aldo-keto reduc-
tase and CYP3A and inhibits CYP3A. Hence, no signiﬁcant
interaction between boceprevir and raltegravir is expected, but
pharmacokinetic drug–drug interaction studies are lacking.
This pharmacokinetic study in healthy volunteers was per-
formed to conﬁrm that a clinically signiﬁcant drug–drug inter-
action between raltegravir and boceprevir is absent.
MATERIALS AND METHODS
Study Design
This open-label, 2-period, randomized, crossover phase 1 trial
was conducted from August to November 2011 at the Radboud
University Nijmegen Medical Centre, Nijmegen, the Nether-
lands. The study was designed to determine the effect of
steady-state boceprevir on the pharmacokinetics of a single
dose of raltegravir by intrasubject comparison. The secondary
objective was to examine the effect of a single dose of raltegravir
on the pharmacokinetics of steady state boceprevir (by compar-
ison with historical controls) and to study the safety of a single-
dose raltegravir coadministered with steady state boceprevir.
Healthy volunteers were equally randomized to 2 treatment
groups. Group A received a single dose of 400 mg of raltegra-
vir on day 10. After a washout period of 2 weeks, the partici-
pants took 800 mg of boceprevir every 8 hours with food for 9
days (days 29–37). On day 38 they received a single dose of
400 mg of raltegravir and 2 doses of 800 mg of boceprevir
(1 together with raltegravir and 1 dose 8 hours later). Group B
received the same regimens but in reversed order. On days 10
and 38, a 12-hour pharmacokinetic curve was recorded.
Procedures
The trial was approved by the Investigational Review Board of
the Radboud University Nijmegen Medical Centre. The trial
was conducted in accordance with Good Clinical Practice and
the Declaration of Helsinki. All participants signed informed
consent prior to screening evaluations.
Study Population
Healthy male and female subjects aged 18–55 years and with a
body mass index (BMI) of 18–30 kg/m2 (extremes included)
were eligible for enrollment. Included participants had to be in a
good, age-appropriate health condition as established by physi-
cal examination, medical history, electrocardiography, and bio-
chemical, hematologic, and urinalysis testing within 4 weeks
prior to day 1. Main exclusion criteria were a history of sensitiv-
ity or idiosyncrasy to medicinal products or excipients; a positive
HIV, hepatitis B or C test result; or the use of any medications
(for 2 weeks preceding dosing) except for acetaminophen.
Study Drug and Dosing
The approved dose of boceprevir (Victrelis, Merck Sharp &
Dohme) is 800 mg every 8 hours with food [6]. In this study,
subjects took 4 capsules of 200 mg of boceprevir at approxi-
mately 08:00 hours, 16:00 hours, and 0:00 hours with a meal
or a snack. A treatment duration of 10 days was chosen to
reach steady state and to assess potential effects on metaboliz-
ing enzymes or drug transporters. Raltegravir (Isentress,
Merck Sharp & Dohme) was administered as a single dose of
400 mg on day 10 and day 38 together with a standardized
breakfast consisting of 2 slices of wheat bread (1 slice with
cheese and 1 with sliced sausage) and 1 glass of milk.
Intake of medication at the clinical trial unit was supervised
and recorded by the study personnel. Drug intake of bocepre-
vir at home was monitored by use of microelectronic monitor-
ing system (MEMS) caps (Aardex, Zug, Switzerland), which
records the opening of the medication bottle. In addition, the
weight of the bottles containing the boceprevir capsules was
recorded on each visit day during boceprevir treatment to
assess adherence. Subjects were asked to write down the exact
times of medication intake in a booklet.
Pharmacokinetic Sampling and Safety Assessments
Blood samples for assessment of pharmacokinetic parameters
of raltegravir were collected during a 12-hour period after
intake of a single dose of 400 mg of raltegravir on days 10 and
38. Blood samples were collected into heparinized tubes and
centrifuged for 10 minutes at 1900 g at 20°C. Plasma was
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transferred to polypropylene tubes and stored at −40°C until
further bioanalysis.
Blood samples for assessment of pharmacokinetic parame-
ters of boceprevir were collected during an 8-hour period after
intake of 800 mg of boceprevir on day 10 or 38. In addition,
blood samples were taken predose on days 1, 3, 6, and 8
(group B) and on days 28, 31, 34, and 36 (group A). Blood
samples for boceprevir were collected into prechilled
potassium-ethylenediaminetetraacetic acid–containing tubes
and centrifuged for 15 minutes at 1500 g at 4°C within 30
minutes after blood collection. Plasma (1.5 mL) was trans-
ferred to prechilled cryovials containing 75 μL of 85% phos-
phoric acid, mixed by a vortex mixer and stored at≤−20°C
within 1 hour of sample collection.
Bioanalytic Methods
Concentrations of raltegravir in plasma were analyzed by use of
a validated reversed-phase high-pressure liquid chromatography
(HPLC) method with ﬂuorescence detection [8]. The linear cali-
bration ranges in plasma were from 0.014 mg/L to 10.0 mg/L.
The raltegravir assay was performed at the laboratory of the
Pharmacy of the Radboud University Nijmegen Medical Centre
and was externally validated through the International Interla-
boratory Quality Control Program for Measurement of Antire-
troviral Drugs in Plasma [9] as well as by the Proﬁciency
Testing Program of the ACTG/IMPAACT group [10].
Boceprevir (SCH503034) is an approximately equal mixture
of 2 diastereomers; SCH534128, the active diastereomer and
SCH534129, which is inactive. The predominant metabolic
pathway produces inactive stereoisomers, together called
SCH629144 [11]. Concentrations of boceprevir were deter-
mined as the sum of concentrations of the 2 diastereomers
SCH534128 and SCH534129. Concentrations of SCH629144
were obtained as the sum of concentrations of 4 analytes, namely,
SCH783004, SCH783005, SCH783006, and SCH783007. The
overall lower limit of quantiﬁcation (LLOQ) was 0.0048 mg/L
for boceprevir and 0.0025 mg/L for SCH629144. The calibration
range for SCH534128 and SCH534129 and for the 4 metabolites
were from the LLOQ to 5.20 mg/L, 4.80 mg/L, and 2.50 mg/L,
respectively. Concentrations of both diastereomers and its meta-
bolites in collected plasma samples were determined using
HPLC–tandem mass spectrometry at PPD Global Central Labs
(Middleton, Wisconsin).
Pharmacokinetic Analysis
Based on the individual plasma concentration-time data, the
following pharmacokinetic parameters of raltegravir were de-
termined: the area under the concentration-time curve from 0
to 12 hours after intake (AUC0–12h), maximum plasma con-
centration (Cmax), time of Cmax (Tmax), the bioavailability ad-
justed volume of distribution (V/F), apparent oral clearance
(CL/F), and the apparent elimination half-life (T1/2). For boce-
previr (both diastereomers and metabolites) the same parame-
ters were determined plus the concentration at 8 hours after
intake (C8h); AUC was determined from 0 to 8 hours after
intake (AUC0–8h). All pharmacokinetic parameters were calcu-
lated by noncompartmental methods using the linear log trap-
ezoidal rule.
Statistical Analysis
The data obtained in this study were analyzed according to an
equivalence approach that is recommended for pharmacoki-
netic interaction studies [12, 13]. The main pharmacokinetic
parameter to be evaluated in this respect was the exposure to
raltegravir, as expressed in the AUC0–12h. The required sample
size was calculated (power of 80%) assuming no difference in
AUC0–12h of raltegravir with or without boceprevir and an in-
trasubject coefﬁcient of variation of 22.5% of raltegravir
AUCs. The required number of participants was 20. Taking
dropouts into account, in total 24 subjects were included in
the study.
The geometric mean ratio estimates of all determined phar-
macokinetic parameters of raltegravir with boceprevir vs ralte-
gravir alone, except for Tmax, were calculated using the mixed
model analysis, with the Kenward-Roger approach for the
evaluation of the ﬁxed effects. In addition, the nonparametric
Wilcoxon signed-rank test was done for Tmax values between
the 2 regimens. Geometric mean ratio estimates with 90%
conﬁdence interval (CI) entirely within the range of 0.80–1.25
were considered to indicate no signiﬁcant interaction.
Pharmacokinetic parameters of boceprevir (diastereomers
and metabolites) were compared with historical data from
healthy volunteers.
Statistical analyses were carried out using SPSS software
version 16.0 or higher (SPSS, Chicago, Illinois) and SAS 9.2.
Descriptive statistics were calculated using Excel 2007 software




Twenty-four healthy volunteers (12 males) were included in the
study. Subjects were of white (n = 22), black (n = 1), or mixed
Asian/white (n = 1) ethnicity. The mean age and BMI were 38
years (range, 20–55 years) and 23 kg/m2 (18–27 kg/m2).
Twenty-two subjects (10 males) completed the trial. One
subject had to discontinue due to nonadherence to the study
protocol and another subject because of elevated alanine ami-
notransferase. Both dropouts completed the raltegravir alone
treatment and remained included in the demographics, safety,
and pharmacokinetic analyses.
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The compliance to boceprevir treatment was good. All but 1
subject (21/22) took all doses of boceprevir and raltegravir ac-
cording to pill count, diary, and MEMS caps recordings. Only
1 subject missed 1 dose of boceprevir. Seven subjects (1–3
times per subject) took the dose of boceprevir outside a 2-
hour time frame (07:00–09:00 hours/15:00–17:00 hours/
23:00–01:00 hours).
Pharmacokinetics
Pharmacokinetic parameters were calculated on all available
data from the 24 subjects included in the trial. The plasma
concentration vs time curves of raltegravir alone and of ralte-
gravir with boceprevir are shown in Figure 1. The pharmaco-
kinetic parameters of raltegravir with and without boceprevir
are shown in Table 1. For raltegravir coadministered with bo-
ceprevir relative to raltegravir alone, the geometric mean ratio
estimates of AUC0–12h and Cmax were 1.04 (90% CI, .88–1.22)
and 1.11 (90% CI, .91–1.36). The geometric mean ratio esti-
mates with 90% CI of the main pharmacokinetic parameter
raltegravir AUC0–12h fell entirely within the range of 0.80 to
1.25, which indicates no signiﬁcant interaction with bocepre-
vir. It is suggested that boceprevir does not inﬂuence the other
pharmacokinetic parameters of raltegravir..
The plasma concentrations vs time curves of boceprevir, the
active diastereomer SCH534128, and the inactive diastereomer
SCH534129 after multiple doses of boceprevir are shown in
Figure 2. The pharmacokinetic parameters of boceprevir, the
diastereomers, and the metabolites together as SCH629144 are
given in Table 2. The AUC0–8h of boceprevir in this study was
5.45 mg  hour/L and in historical controls the AUC0–8h of
boceprevir was 5.41 mg  hour/L [6]. No differences in expo-
sure to boceprevir or the individual diastereomers were ob-
served compared with historical controls.
Adverse Events and Safety Assessments
No serious adverse events were reported. In total, 90 adverse
events were reported by 22 subjects after intake of study medi-
cation. The most frequently reported adverse experiences that
were possibly, probably, or deﬁnitely drug-related are shown
in Table 3. Two adverse events (creatine kinase elevation and
myalgia) were reported as grade 4 of intensity. All other
adverse events were grade 1 or 2 of intensity. No additional
side effects were seen when raltegravir was added to steady
state boceprevir.
Figure 1. Geometric mean plasma concentrations of raltegravir follow-
ing a single dose of 400 mg raltegravir in the presence and absence of
steady-state boceprevir.
Table 1. Comparison of Single-Dose Pharmacokinetic Parameters of Raltegravir With or Without Coadministration of Multiple Doses
of Boceprevir in Healthy Volunteers
No.
RAL + BOC, Geometric






AUC0–12h (mg * h/L) 22 4.27 (3.22–5.66) 24 4.04 (3.09–5.28) 22 1.04 (.88–1.22)
Cmax (mg/L) 22 1.06 (.76–1.49) 24 0.93 (.70–1.23) 22 1.11 (.91–1.36)
Tmax (h)
b 22 5.00 (1.00–12.00) 24 4.00 (1.00–12.03) 22
V/F (L) 19 261.2 (176.6–386.2) 19 335.3 (234.8–478.9) 17 0.75 (.58–.98)
CL/F (L/h) 19 82.5 (58.0–117.3) 19 81.4 (54.8–120.9) 17 0.99 (.73–1.35)
T1/2 (h) 15 1.83 (1.42–2.34) 13 1.80 (1.31–2.47) 10 0.98 (.74–1.30)
Data are geometric mean (95% CI) values, unless otherwise indicated.
Abbreviations: AUC0–12h, area under the plasma concentration-time curve 0-12 hours after intake; BOC, boceprevir; CI, confidence interval; CL/F, apparent oral
clearance; Cmax, maximum plasma concentration; RAL, raltegravir; T1/2, elimination half-life; Tmax, time to reach Cmax; V/F, volume of distribution.
a The number of paired samples per parameter is given.
b For Tmax, median + range is reported; the result of the Wilcoxon signed-rank test was P = .312.
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No signiﬁcant difference was observed for the most important
pharmacokinetic parameter of raltegravir, AUC0–12h, between
raltegravir alone and raltegravir in combination with bocepre-
vir. Exposure to boceprevir in the presence of raltegravir was
comparable to historical controls. Because boceprevir interacts
with many other ﬁrst-line antiretroviral drugs, it is relevant to
know that boceprevir combined with raltegravir is a good
treatment option for HIV/HCV-coinfected patients because of
the absence of a clinically signiﬁcant drug–drug interaction.
Boceprevir and telaprevir have shown some extensive drug–
drug interactions with various drugs and drug classes. Several
drug combinations with boceprevir or telaprevir should be
avoided or should be used with great caution. These HCV
protease inhibitors can be the perpetrator or victim of such
interactions. Since there is an association between boceprevir
and telaprevir exposure and HCV decline [14–16], a reduction
in plasma concentrations might lead to a decreased efﬁcacy of
treatment or even to resistance.
An explanation for the large number of drug–drug interac-
tions with boceprevir and telaprevir, is that both HCV prote-
ase inhibitors are substrates and inhibitors of the CYP3A
enzyme [6, 7, 17, 18], which is responsible for the metabolism
of numerous drugs. Besides that, they are also substrates and
inhibitors of P-glycoprotein (P-gp) [6, 7, 17, 18], an efﬂux
transporter that plays a signiﬁcant role in the absorption and
elimination of many drugs.
At this moment, there are a number of studies performed
on potential drug–drug interactions with the HCV protease
inhibitors and antiretroviral drugs. Boceprevir did not inﬂu-
ence the AUC of the NRTI tenofovir [19]. The nonnucleoside
reverse transcriptase inhibitor efavirenz is known to induce
CYP3A enzymes and P-gp transporters and boceprevir AUC
and trough concentrations were reduced by 19% and 44%, re-
spectively, in combination with efavirenz [19]; this combina-
tion should be avoided. When the HIV protease inhibitors
boosted with ritonavir are coadministered with telaprevir or
boceprevir, higher concentrations of the HCV protease inhibi-
tors were theoretically expected (due to CYP3A inhibition by
ritonavir), but controversially, concentrations were found to
be lower. Trough concentrations of boceprevir were 18%, 35%,
and 57% lower in combination with boosted atazanavir, daru-
navir, and lopinavir, respectively [20]. In addition, decreased
concentrations of the HIV protease inhibitors were found
when taken with boceprevir.
Until now, the effect of boceprevir on raltegravir or vice
versa was not known, but a drug–drug interaction was not
Figure 2. Geometric mean plasma concentrations of boceprevir,
SCH534128, and SCH534129 after multiple doses of boceprevir 800 mg
and a single dose of raltegravir 400 mg.
Table 2. Pharmacokinetic Parameters of Multiple Doses of Boceprevir in Healthy Volunteers
No.a
Boceprevir SCH534128 (active) SCH534128 (inactive)
SCH629144
(metabolites)
GM (95% CI) GM (95% CI) GM (95% CI) GM (95% CI)
AUC0–8h (mg * h/L) 22 5.45 (5.11–5.81) 3.74 (3.50–4.01) 1.69 (1.56–1.82) 22.69 (19.94–25.83)
Cmax (mg/L) 22 1.88 (1.72–2.06) 1.23 (1.13–1.35) 0.65 (.59–.73) 5.19 (4.53–5.95)
Tmax (h)
b 22 3.00 (1.50–5.00) 3.00 (1.50–5.00) 2.00 (1.50–5.00) 4.00 (2.00–5.00)
C8h (mg/L) 22 0.09 (.07–.11) 0.07 (.06–.08) 0.02 (.01–.02) 1.30 (1.04–1.62)
V/F (L) 22 224.5 (201.6–250.0) 334.2 (298.7–373.9) 671.6 (587.7–767.4) 73.9 (64.1–85.2)
CL/F (L/h) 22 143.0 (133.9–152.7) 207.0 (193.1–221.9) 467.1 (431.9–505.2) 30.7 (26.7–35.1)
T1/2 (h) 20 1.10 (1.04–1.17) 1.14 (1.07–1.21) 1.01 (.94–1.08) 1.65 (1.49–1.84)
Abbreviations: AUC0–8h, area under the plasma concentration-time curve 0–8 hours after intake; C8h, concentration at 8 hours after intake; CI, confidence
interval; CL/F, apparent oral clearance; Cmax, maximum plasma concentration; GM, geometric mean; T1/2, elimination half-life; Tmax, time to reach Cmax; V/F,
volume of distribution.
a n = 13 for the SCH629144 T1/2.
b For Tmax, median (range) has been reported.
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expected based on the pharmacokinetic characteristics of both
drugs. Boceprevir is metabolized by 2 distinctive pathways,
mainly through ketone reduction by aldo-keto reductase
(AKR1C2 and AKR1C3) and to a lesser extent by CYP3A4 and
CYP3A5 [6, 7]. Because the biotransformation and clearance of
boceprevir involves 2 different enzymatic pathways, it is less
likely to be subject to signiﬁcant drug–drug interactions with
concomitant medication affecting only 1 of these pathways. Bo-
ceprevir is a strong inhibitor of CYP3A4 and CYP3A5 [6, 7].
Raltegravir is not a substrate of CYP and does not inﬂuence
CYP-mediated metabolism of other agents [21, 22]. It is a P-gp
substrate [23], and is metabolized by UGT but does not itself
inﬂuence UGT-mediated metabolism of other agents [21, 22].
Because raltegravir is not a CYP3A substrate and thus will
not be affected by the strong inhibition of CYP3A by bocepre-
vir, and because raltegravir is metabolized by UGT but boce-
previr is not known to inﬂuence UGT, a major drug–drug
interaction is unlikely with this combination. A minor interac-
tion may occur through inhibition of P-gp mediated transport
of raltegravir by boceprevir.
However, even when no drug interaction is expected theo-
retically, it may be recommended to collect sufﬁcient clinical
evidence to support this hypothesis because unexpected inter-
actions with antiretroviral agents have been observed in the
past. This is also true for raltegravir; for instance, there is a
17% decrease in atazanavir AUC0–12h when combined with
raltegravir [24], and combined use of tenofovir and raltegravir
leads to 49% increase in raltegravir AUC [25].
Since raltegravir has been demonstrated to be a drug with a
low interaction proﬁle and in general is the victim and not the
perpetrator of drug–drug interactions, the primary objective of
this study was to determine the effect of multiple doses of
boceprevir on the pharmacokinetics of a single dose of ralte-
gravir. Because inﬂuence of raltegravir on boceprevir was con-
sidered unlikely, and to reduce exposure of the drugs to
healthy volunteers, we chose to perform a 1-way interaction
study and therefore compared the pharmacokinetic data on
boceprevir found in our study with data from historical con-
trols. In light of other unexpected ﬁndings from drug–drug
interaction studies with boceprevir [20] that are known at this
moment, a 2-way interaction study would be preferred in
order to compare the boceprevir pharmacokinetics with and
without raltegravir intraindividually. Our study was conducted
in healthy volunteers, limiting our interpretation in HIV/
HCV-coinfected patients. There are few data on the pharma-
cokinetics of a single dose of 400 mg raltegravir in the target
population. The pharmacokinetics of boceprevir are not differ-
ent in HCV-positive or -negative patients [6, 7], but in patients
with cirrhosis higher plasma concentrations of boceprevir are
found [6]. It is, however, not likely that higher concentrations
of boceprevir and/or raltegravir will affect the possibility of an
interaction between these drugs.
Phase 2 clinical trials with boceprevir in HIV-coinfected pa-
tients is ongoing and interim results seem to be promising
[26]. Twelve weeks after therapy with boceprevir added to pe-
gylated interferon-alfa and ribavirin, 60.7% of patients had an
undetectable HCV load vs 26.5% of patients on standard of
care only. In the study with boceprevir, patients were not
allowed to use efavirenz and the number of patients on ritona-
vir-boosted HIV protease inhibitors or raltegravir was small.
Unfortunately, drug concentration data have not yet been pre-
sented and, therefore, up till now, it remains unknown if
reduced drug concentrations have contributed to HIV or
HCV breakthroughs.
Table 3. Most Frequently Reported Treatment Drug-Related Adverse Events in Number of Subjects Reporting This Adverse Event
Adverse Effect
Raltegravir
(n = 24) (%)
Washout
Raltegravir
(n = 12) (%)
Boceprevir
(n = 22) (%)
Boceprevir +
Raltegravir
(n = 22) (%)
Washout
Boceprevir + Raltegravir
(n = 10) (%) Total (n = 24) (%)
Dysgeusia 17 (77) 17 (77)
Headache 2 (17) 4 (18) 3 (14) 8 (33)
Atypical lymphocytes 3 (14) 3 (14)
Nausea 3 (14) 3 (13)
Xerostomia 3 (14) 3 (13)
Elevated ALT 2 (9) 1 (10) 3 (13)
Myalgia 1 (8) 2 (9) 2 (8)
Sore throat 2 (9) 2 (8)
Dyspepsia 2 (9) 2 (8)
Elevated AST 1 (5) 1 (10) 2 (8)
Diarrhea 1 (5) 1 (5) 2 (8)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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In conclusion, coadministration of multiple-dose boceprevir
with raltegravir did not meaningfully affect single-dose ralte-
gravir exposure. Steady-state boceprevir exposure after coad-
ministration with a single dose of raltegravir was comparable
to the exposure of boceprevir administered alone as reported
for historical controls. Due to the absence of a clinically signif-
icant drug-drug interaction, raltegravir can be recommended
for combined HIV/HCV treatment including boceprevir. In
the groups of healthy volunteers participating in this study,
coadministration of single-dose raltegravir to steady-state bo-
ceprevir was safe and well tolerated.
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